Citadel Advisors
DSGN icon

Citadel Advisors’s Design Therapeutics DSGN Stock Holding History

Citadel Advisors’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,100
Closed -$12K – 13073
2025
Q1 		$12K Buy
3,100
+500
+19% +$2.39K ﹤0.01% 13464
2024
Q4 		$16K Sell
2,600
-100
-4% -$579 ﹤0.01% 13329
2024
Q3 		$14.5K Sell
2,700
-4,300
-61% -$20.2K ﹤0.01% 13018
2024
Q2 		$23.4K Buy
7,000
+6,900
+6,900% +$26.9K ﹤0.01% 12496
2024
Q1 		$403 Sell
100
-2,900
-97% -$7.75K ﹤0.01% 14341
2023
Q4 		$7.95K Sell
3,000
-700
-19% -$1.6K ﹤0.01% 13259
2023
Q3 		$8.73K Sell
3,700
-500
-12% -$2.33K ﹤0.01% 13164
2023
Q2 		$26.5K Sell
4,200
-4,400
-51% -$26.9K ﹤0.01% 12490
2023
Q1 		$49.6K Sell
8,600
-3,000
-26% -$22.4K ﹤0.01% 12154
2022
Q4 		$119K Buy
+11,600
New +$157K ﹤0.01% 10978

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's DSGN Position: Q1 2026 in Review

Citadel Advisors reduced its Design Therapeutics (DSGN) stake by 50% in Q1 2026, selling an estimated $2.31M and leaving 231,513 shares worth $2.46M. The position accounts for ﹤0.01% of the portfolio, ranked #5655.

Citadel Advisors first reported a position in DSGN in Q1 2021 and has held it in 21 quarters since. The position peaked at $75.8M in Q1 2021. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Citadel Advisors held 231,513 shares of Design Therapeutics worth $2.46M as of Q1 2026.
  • Citadel Advisors sold 228,361 Design Therapeutics shares in Q1 2026, an estimated $2.31M.
  • Design Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5655 holding.
  • Citadel Advisors first reported a position in Design Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Citadel Advisors's Design Therapeutics position peaked at $75.8M in Q1 2021.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.